“Vaccinating pregnant women is crucial, and a way of plugging the “immunisation loophole” and protecting their unborn babies.
In 2012, a nationwide outbreak of whooping cough swept across the UK.
Almost 12,000 people were struck down by the highly infectious disease, which is marked by paroxysmal coughing – accompanied in some cases by the distinctive “whoop” – and can cause severe complications and death.
Newborn babies are especially vulnerable, and, in the three years from 2012 to 2014, a total of 24 babies died under the age of three months old. Thousands more were admitted to hospital.
The sudden upsurge came after more than a decade in which the number of cases had remained in the hundreds.
It proved, in tragic fashion, the vital importance of vaccinating the mother to protect her soon-to-be-born child.
For although whooping cough (known by the medical term pertussis) is a vaccine-preventable disease, the vaccine does not work in those most at risk – babies under three months.
Their developing immune systems are unable to mount the protective response that vaccination in an older infant will trigger
To ensure protection for newborns via their mothers, all pregnant women in the UK have been offered the pertussis vaccine in the third trimester of pregnancy since 2012, but many resist because of misplaced fears about its safety.
Today, it is combined with vaccines against polio, diphtheria and tetanus – diseases that have been virtually eliminated from the UK but could make a comeback.
The combined vaccine, called Boostrix IPV, had a take up rate in England of 62% in 2014.”
More: The power of vaccinating pregnant women
Note: Mad, mad pharma, let’s move to the mother. Inject foreign dna and toxins during pregnancy. How can they even claim to have done studies which would be highly unethical! Who makes Boostrix IPV? GlaxoSmithKline!
“Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or post-natal development
BOOSTRIX-IPV should not be administered to subjects who have experienced neurological complications following an earlier immunisation against diphtheria and/or tetanus (for convulsions or hypotonic-hyporesponsive episodes”